title: Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'--authors' reply.
authors.affiliation: Department of Rheumatology, Leiden University Medical Center, C-01-R, PO BOX 9600, 2300 RC, Leiden, The Netherlands. i.m.markusse@lumc.nl.
authors.forename: Iris M
authors.initials: IM
authors.lastname: Markusse
authors.affiliation: Department of Rheumatology, VU Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. wf.lems@vumc.nl.|Department of Rheumatology, Reade, location dr. Jan van Breemenstraat, PO Box 58271, 1040 HG, Amsterdam, The Netherlands. wf.lems@vumc.nl.
authors.forename: Willem F
authors.initials: WF
authors.lastname: Lems
authors.affiliation: Department of Rheumatology, Leiden University Medical Center, C-01-R, PO BOX 9600, 2300 RC, Leiden, The Netherlands. t.w.j.huizinga@lumc.nl.
authors.forename: Tom W J
authors.initials: TW
authors.lastname: Huizinga
authors.affiliation: Department of Rheumatology, Leiden University Medical Center, C-01-R, PO BOX 9600, 2300 RC, Leiden, The Netherlands. c.f.allaart@lumc.nl.
authors.forename: Cornelia F
authors.initials: CF
authors.lastname: Allaart
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate